Alexandria Pharmaceuticals stock gets fresh earnings reference
Published on 11/16/2026 at 00:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSQuarterly earnings set new reference
- Net profit reached EGP 133.50 million in the three months through September 2026, up from EGP 103.74 million a year earlier.
- The disclosure covers Alexandria Pharmaceuticals' first quarter of fiscal 2026/2027.
Alexandria Pharmaceuticals reported net profit of EGP 133.50 million for the three months ended September 30, 2026, according to a FoudaLens disclosure published on November 15. The filing identifies Alexandria Pharmaceuticals and ISIN EGS38341C011 and cites the company as the source.
Profit advances in first quarter
Net profit was EGP 133.50 million for the July-to-September period, compared with EGP 103.74 million in the corresponding quarter of fiscal 2025/2026. The increase calculated from the two reported amounts is approximately 28.69 percent.
The disclosure covers the opening quarter of fiscal 2026/2027. A limited-review report and financial statements in Arabic and English were attached to the filing, giving investors a new earnings reference for the current financial year.
Dividend dates remain ahead
Alexandria Pharmaceuticals has also set a cash dividend of EGP 80 per share for the completed 2025/2026 financial year. The entitlement date is November 23, 2026, and payment is scheduled to begin on November 26, according to the Egyptian Exchange disclosure summarized in the sector coverage.
Alexandria Pharmaceuticals at a glance
- Company: Alexandria Pharmaceuticals
- ISIN: EGS38341C011
- Ticker: AXPH
- Home exchange: Egyptian Exchange
- Reporting period: July 1 to September 30, 2026
- Net profit: EGP 133.50 million
The Egyptian market backdrop is covered in the Current market reports.
More news and analyses on Alexandria Pharmaceuticals stock are available here.
